Richard R. Burgess
Founder at Atterx Biotherapeutics, Inc.
Profile
Richard R.
Burgess is the founder of Atterx Biotherapeutics, Inc. (founded in 2001) where he holds the title of Director since 2013.
He is currently working at Harvard University as an Oncology Professor.
In his former positions, he served as Chairman at NeoClone Biotechnology International LLC, Research Director at Genetic Systems Corp., Director at University of Wisconsin Biotechnology Center (in 1996), and Professor at the University of Wisconsin.
Dr. Burgess obtained a doctorate degree from Harvard University in 1969 and an undergraduate degree from the California Institute of Technology in 1964.
Richard R. Burgess active positions
Companies | Position | Start |
---|---|---|
Atterx Biotherapeutics, Inc.
Atterx Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Atterx Biotherapeutics, Inc. develops novel antibacterial technologies. It developed two products to fight multi-drug resistant, Gram negative bacteria. The first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections and GN-4474 has been developed using this technology to target Gram negative bacteria. It has been shown to be effective in animal infection models and an IND filing is expected in 2015. The company was founded by Richard R. Burgess and Marcin Filutowicz in 2001 and is headquartered in Madison, WI. | Founder | 03/08/2009 |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Former positions of Richard R. Burgess
Companies | Position | End |
---|---|---|
University of Wisconsin Biotechnology Center
University of Wisconsin Biotechnology Center Miscellaneous Commercial ServicesCommercial Services The University of Wisconsin Biotechnology Center provides core facilities for various biotechnology services such as bioinformatics, next-generation sequencing, genome editing, animal models, gene expression, mass spectrometry, and isotope ratio mass spectrometry. The center is based in Madison, WI. The center also offers outreach programs such as Biogarage and Biotrek. Payment instructions are included on the invoice for external customers. | Director/Board Member | 01/01/1996 |
University of Wisconsin | Corporate Officer/Principal | - |
Genetic Systems Corp. | Chief Tech/Sci/R&D Officer | - |
NeoClone Biotechnology International LLC
NeoClone Biotechnology International LLC BiotechnologyHealth Technology NeoClone Biotechnology International LLC engages in the production and supply of monoclonal antibody products. The firm offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, and interferon gamma, as well as offers cancer antibodies and Softag products. It provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. The company was founded in 1999 by Mark Jackson, Donal Kaehler, David Largaspaeda and Deven McGlenn and is headquartered in Madison, WI. | Chairman | - |
Training of Richard R. Burgess
Harvard University | Doctorate Degree |
California Institute of Technology | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Atterx Biotherapeutics, Inc.
Atterx Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Atterx Biotherapeutics, Inc. develops novel antibacterial technologies. It developed two products to fight multi-drug resistant, Gram negative bacteria. The first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections and GN-4474 has been developed using this technology to target Gram negative bacteria. It has been shown to be effective in animal infection models and an IND filing is expected in 2015. The company was founded by Richard R. Burgess and Marcin Filutowicz in 2001 and is headquartered in Madison, WI. | Health Technology |
NeoClone Biotechnology International LLC
NeoClone Biotechnology International LLC BiotechnologyHealth Technology NeoClone Biotechnology International LLC engages in the production and supply of monoclonal antibody products. The firm offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, and interferon gamma, as well as offers cancer antibodies and Softag products. It provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. The company was founded in 1999 by Mark Jackson, Donal Kaehler, David Largaspaeda and Deven McGlenn and is headquartered in Madison, WI. | Health Technology |
Genetic Systems Corp. | |
University of Wisconsin Biotechnology Center
University of Wisconsin Biotechnology Center Miscellaneous Commercial ServicesCommercial Services The University of Wisconsin Biotechnology Center provides core facilities for various biotechnology services such as bioinformatics, next-generation sequencing, genome editing, animal models, gene expression, mass spectrometry, and isotope ratio mass spectrometry. The center is based in Madison, WI. The center also offers outreach programs such as Biogarage and Biotrek. Payment instructions are included on the invoice for external customers. | Commercial Services |
- Stock Market
- Insiders
- Richard R. Burgess